3 Segment information
Business segments1
2007
Continuing operations
Discon-
tinued
operations
Total
Nutrition
Pharma
Performance
Materials
Industrial
Chemicals
Other
activities2
Elimina-
tions
Total
Financial performance
 
 
 
 
 
 
 
 
 
Net sales
2,543
981
2,895
1,937
401
-
8,757
-
8,757
Supplies to other clusters
47
50
6
268
54
(425)
-
-
-
 
 
 
 
 
 
 
 
 
 
Supplies
2,590
1,031
2,901
2,205
455
(425)
8,757
-
8,757
 
 
 
 
 
 
 
 
 
 
Operating profit before exceptional items
264
93
321
225
(80)
-
823
-
823
Exceptional items
(22)
(154)
-
-
-
-
(176)
-
(176)
 
 
 
 
 
 
 
 
 
 
Operating profit
242
(61)
321
225
(80)
-
647
-
647
 
 
 
 
 
 
 
 
 
 
Depreciation and amortization
141
81
94
67
41
-
424
-
424
Additions to provisions
32
13
10
4
23
-
82
-
82
Share of the profit of associates
-
-
-
(1)
(1)
-
(2)
-
(2)
R&D costs
136
68
131
23
14
-
372
-
372
R&D costs / net sales (in %)
5.3
6.9
4.5
1.2
3.5
-
4.2
-
4.2
Wages, salaries and social security costs
469
206
291
99
282
-
1,347
-
1,347
 
 
 
 
 
 
 
 
 
 
Financial position
 
 
 
 
 
 
 
 
 
Total assets
3,527
1,669
2,958
1,478
9,749
(9,553)
9,828
-
9,828
Total liabilities
1,661
1,463
1,484
913
4,013
(5,089)
4,445
-
4,445
Capital employed at year-end
2,067
1,095
1,815
714
291
-
5,982
-
5,982
Capital expenditure and acquisitions
145
65
214
90
54
-
568
-
568
Share in equity of associates
1
1
0
12
6
-
20
-
20
 
 
 
 
 
 
 
 
 
 
EBITDA / net sales
(in %)
15.9
17.7
14.3
15.1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Workforce3
 
 
 
 
 
 
 
 
 
Average
7,508
5,013
4,826
2,141
2,945
-
22,433
-
22,433
Year-end
7,782
5,073
5,139
2,134
3,126
-
23,254
-
23,254
1 For a description of the types of products and services of each segment please refer to the review of business in the report by the Managing Board.
2 Other activities also includes costs for defined benefit plans, corporate overhead and share-based compensation. A reasonable basis for the allocation of the costs for defined benefit plans to the individual clusters is not available, because these costs relate to both current and former employees.
3 The workforce of joint ventures has been included on a proportionate basis.
Transfers between segments were fairly limited and were generally executed at market-based prices.
Business segments1
2006
Continuing operations
Discon-
tinued
operations
Total
Nutrition
Pharma
Performance
Materials
Industrial
Chemicals
Other
activities2
Elimina-
tions
Total
Financial performance
 
 
 
 
 
 
 
 
 
Net sales
2,407
916
2,753
1,872
404
-
8,352
28
8,380
Supplies to other clusters
56
51
6
263
18
(394)
-
-
-
 
 
 
 
 
 
 
 
 
 
Supplies
2,463
967
2,759
2,135
422
(394)
8,352
28
8,380
 
 
 
 
 
 
 
 
 
 
Operating profit before exceptional items
314
65
329
196
(69)
-
835
(1)
834
Exceptional items
(44)
(14)
11
(6)
27
-
(26)
-
(26)
 
 
 
 
 
 
 
 
 
 
Operating profit
270
51
340
190
(42)
-
809
(1)
808
 
 
 
 
 
 
 
 
 
 
Depreciation and amortization
150
81
100
73
36
-
440
-
440
Additions to provisions
48
15
9
3
32
-
107
-
107
Share of the profit of associates
1
0
0
0
0
-
1
-
1
R&D costs
140
59
115
21
12
-
347
-
347
R&D costs / net sales (in %)
5.8
6.4
4.2
1.1
3.0
-
4.2
-
4.2
Wages, salaries and social security costs
455
204
270
97
260
-
1,286
2
1,288
 
 
 
 
 
 
 
 
 
 
Financial position
 
 
 
 
 
 
 
 
 
Total assets
3,466
1,734
2,998
1,390
9,690
(9,187)
10,091
-
10,091
Total liabilities
1,688
1,524
1,395
855
3,851
(5,077)
4,236
-
4,236
Capital employed at year-end
2,159
1,302
1,697
745
407
-
6,310
(7)
6,303
Capital expenditure and acquisitions
113
146
126
68
48
-
501
-
501
Share in equity of associates
1
2
0
13
10
-
26
-
26
 
 
 
 
 
 
 
 
 
 
EBITDA / net sales
(in %)
19.3
15.9
15.6
14.4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Workforce3
 
 
 
 
 
 
 
 
 
Average
7,466
4,558
4,410
2,187
2,788
-
21,409
27
21,436
Year-end
7,711
4,732
4,664
2,183
2,860
-
22,150
6
22,156
1 For a description of the types of products and services of each segment please refer to the review of business in the report by the Managing Board.
2 Other activities also includes costs for defined benefit plans, corporate overhead and share-based compensation. A reasonable basis for the allocation of the costs for defined benefit plans to the individual clusters is not available, because these costs relate to both current and former employees.
3 The workforce of joint ventures has been included on a proportionate basis.
Transfers between segments were fairly limited and were generally executed at market-based prices.
Geographical segments
2007
Continuing operations
The
Netherlands
Rest of
Europe
North
America
China
Rest of
Asia-
Pacific
Rest of
the world
Elimina-
tions
Total
Net sales by origin
 
 
 
 
 
 
 
 
In € million
3,829
2,477
1,143
536
433
339
-
8,757
In %
44
28
13
6
5
4
-
100
 
 
 
 
 
 
 
 
 
Net sales by destination
 
 
 
 
 
 
 
 
In € million
793
3,726
1,566
698
1,162
812
-
8,757
In %
9
43
18
8
13
9
-
100
 
 
 
 
 
 
 
 
 
Total assets
9,415
4,793
1,447
587
393
545
(7,352)
9,828
 
 
 
 
 
 
 
 
 
Property, plant and equipment
 
 
 
 
 
 
 
 
Capital expenditure
212
85
78
36
5
11
-
427
Carrying amount
1,328
1,265
488
272
49
38
 
3,440
 
 
 
 
 
 
 
 
 
Workforce1 at year-end
7,219
7,124
2,768
3,564
1,268
1,311
-
23,254
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2006
 
 
 
 
 
 
 
 
 
Net sales by origin
 
 
 
 
 
 
 
 
In € million
3,802
2,276
1,193
451
376
254
-
8,352
In %
46
27
14
5
5
3
-
100
 
 
 
 
 
 
 
 
 
Net sales by destination
 
 
 
 
 
 
 
 
In € million
808
3,537
1,617
618
1,090
682
-
8,352
In %
10
42
19
8
13
8
-
100
 
 
 
 
 
 
 
 
 
Total assets
9,402
3,682
1,523
576
413
508
(6,013)
10,091
 
 
 
 
 
 
 
 
 
Property, plant and equipment
 
 
 
 
 
 
 
 
Capital expenditure
128
135
101
38
13
3
-
418
Carrying amount
1,365
1,368
520
304
61
37
-
3,655
 
 
 
 
 
 
 
 
 
Workforce1 at year-end
7,057
6,976
2,659
3,031
1,188
1,239
-
22,150
1 The workforce of joint ventures has been included on a proportionate basis.